The primary reasons for performing ANOVA-based screening of WGCNA modules were identification of clinically significant modules and their key networks/upstream regulators and further investigation of the disease mechanisms affected differentially under the different driver EGFR mutations in lung adenocarcinoma. The gene discussed is EGFR; the disease is lung adenocarcinoma.